YK Bioventures is a California-based venture capital firm dedicated to helping scientists and entrepreneurs bring new technologies and treatments to patients. The firm invests in healthcare and biotechnology companies across the United States at an early stage.
68% of their portfolio is in Biotech & Life Sciences. Deal activity increased 400% year-over-year (5 deals in the last 12 months). Their most common stage is series-a (42% of deals). Average disclosed round size is $72.7M (across 17 rounds with reported amounts).
Portfolio
14
Fund Size
$100M
Top Stage
Series A
Last 12 Mo
5
Team
GY
Gary Yeung
Founder & Managing Partner
YK
Young-Guen Kwon
Managing Partner
BK
Benjamin Kaeser
Associate
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
19 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Think Bioscience | Series A | $55M | Jan 2026 |
 Psithera | Series A | $47.5M | Dec 2025 |
 Triana Biomedicines | Series B | $120M | Dec 2025 |
 Protego | Series B | $130M | Dec 2025 |
| PProtego Biopharma | Series B | $130M | Dec 2025 |
 Neurona Therapeutics | Unknown | $102M | Apr 2025 |
 Neurona | Series A | $102M | Jan 2025 |
| PProtego Biopharma | Series B | $130M | Jan 2025 |
| Think Bioscience | Seed | $6M | May 2024 |
 Tempo Therapeutics, Inc. | Series A | $12M | Mar 2024 |
 Pelage Pharmaceuticals | Series A | $14M | Feb 2024 |
 Judo Bio | Series A | — | — |
 Moonwalk Biosciences | Unknown | $57M | — |
 Vivere Oncotherapies | Unknown | $10M | — |
 āshibio | Seed | $40M | — |
| āshibio | Series A | $40M | — |
| PPelage | Series B | $120M | — |
| Pelage Pharmaceuticals | Series B | $120M | — |
| PPelage | Series A | — | — |
Top Co-Investors
GV5 shared
ARCH Venture Partners5 shared
Visionary Ventures4 shared
Main Street Advisors4 shared
Lightspeed Venture Partners4 shared
Digitalis Ventures4 shared
Agent Capital3 shared
Omega Funds3 shared
Forbion3 shared
Alexandria Venture Investments3 shared
Euclidean Capital3 shared
MPM Capital3 shared
ReGen Ventures2 shared
Atlas Venture2 shared
Schroders Capital2 shared
Ysios Capital2 shared
Cormorant Asset Management2 shared
Viking Global Investors2 shared
LYFE Capital2 shared
UC Investments2 shared
Last updated: 7 October 2026